Yarden Kahlon‐Suki

Yarden Kahlon‐Suki

Auto-generated profile, based on publicly available information

Yarden Kahlon‐Suki

Faculty of Dental Medicine The Hebrew University of Jerusalem Jerusalem Israel

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 July 2025 in The FASEB Journal
Verified
Journal Article
Open access
OHOmer Helwa-Shalom
Omer Helwa-Shalom
YKYarden Kahlon‐Suki
Yarden Kahlon‐Suki
SMShany Ivon Markowitz
Shany Ivon Markowitz
KGKoby Goren
Koby Goren
DSDekel Shilo
Dekel Shilo
AHAmir Haze
Amir Haze
Previous studies have demonstrated that recombinant human amelogenin protein (rHAM + ) promotes healing of injured articular cartilage, subchondral bone, and skeletal ligaments. Therefore, we speculated that amelogenin may play a role in osteoarthritis (OA) development. Aged amelogenin‐null and wild‐type mice underwent micro‐computed tomography (micro‐CT) and histological analyses to assess OA‐related changes. Additionally, OA was induced in rat knees via destabilization of the medial meniscus, followed by treatment with 0.5 mg/mL rHAM + dissolved in propylene glycol alginate (PGA) or PGA alone. Magnetic resonance imaging (MRI) and histological analyses were performed. Twenty‐three‐month‐old amelogenin‐null mice exhibited severe OA features, including cartilage loss, joint space narrowing, and osteophyte formation, whereas wild‐type mice showed only mild, age‐related changes. OA pathology was evident in 12‐month‐old amelogenin‐null mice, by increased matrix metalloproteinase‐13 (MMP‐13) and decreased type II collagen expression. In osteoarthritic rats, MRI analyses demonstrated that treatment with rHAM + delayed disease progression and improved OA phenotypes. Twenty‐four weeks posttreatment, the levels of type II collagen increased, while MMP‐13 and type X collagen decreased. MMP‐13 reduction was detected as early as 2 weeks posttreatment, contributing to cartilage preservation. Furthermore, similar to the known effect of rHAM + in acute injuries, recruitment of CD105‐positive mesenchymal stem cells to the cartilage was detected 5 days posttreatment. Lack of amelogenin led to the development of osteoarthritic phenotypes, whereas in the induced osteoarthritis model, a single application of amelogenin inhibited joint deterioration and partially healed osteoarthritic damage compared with the control. These findings highlight the potential of amelogenin as a disease‐modifying agent for OA.